ISRCTN10957794
Suspended
Phase 2
A phase I/II first-in-human, open-label, dose-escalation study to evaluate the safety and efficacy of a single intravenous (IV) administration of ECUR-506 in males less than 9 months of age with genetically confirmed neonatal onset ornithine transcarbamylase (OTC) deficiency
Fortrea Development Ltd0 sites13 target enrollmentMay 7, 2024
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Ornithine Transcarbamylase (OTC) Deficiency
- Sponsor
- Fortrea Development Ltd
- Enrollment
- 13
- Status
- Suspended
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Male sex
- •2\. Gestational age \= 37 weeks
- •3\. Age at screening is 24 hours to 7 months
- •4\. Genetically confirmed OTC deficiency (OTCD). Documented analysis either through prenatal testing or post\-birth genetic testing. Note: a prenatal testing diagnosis will be confirmed post\-birth and prior to dosing.
- •5\. Severe neonatal OTCD defined by the following:
- •5\.1\. Current or past hyperammonemic crisis (which includes but is not limited to: severely elevated \[\>8 x ULN] ammonia levels, lethargy, poor feeding, coma, seizure) within first week of life
- •5\.2\. Family history and genetic confirmation of pathogenic or likely pathogenic variant consistent with severe OTCD, or has same genetic mutation as previous family member who had severe disease with neonatal onset within first week of life
- •5\.3\. Currently receiving treatment (e.g., dietary and scavenger therapy)
- •6\. In participants not prenatally diagnosed, current or historical (within 2 weeks prior to Screening) biochemical profile consistent with OTCD: below LLN of plasma citrulline/arginine and urine orotic aciduria at time of diagnosis
- •7\. Participant’s parents/legally authorized representative must be able to comprehend and be willing to provide a signed IRB/IEC\-approved ICF which will include consent for participation in this 24 week protocol with immediate roll\-over into the 14\.5 year long term follow\-up (ECUR\-LTFU) study.
Exclusion Criteria
- •1\. Neonatal diagnosis of severe to profound Hypoxic Ischemic Encephalopathy (based on standard HIE metrics) due to birth injury
- •2\. Requiring urgent liver transplant due to liver failure as assessed by the PI.
- •3\. Contiguous gene deletion involving the OTC gene
- •4\. Known or suspected major organ injury/dysfunction/anomalies (brain, heart, liver, kidneys) other than what is consistent with OTCD, based on routine medical assessments performed as part of standard of care
- •5\. Treatment with any other gene therapy or gene editing therapy
- •6\. Co\-enrollment in any other clinical study with an investigational product prior to or during the duration of this protocol would require the participant to be withdrawn from this study
- •7\. Any condition, that in the opinion of the Investigator, would compromise the safety of the participant or study data
- •8\. Documented vertical transmission of HSV, HIV, or HepA/HepB/HepC
- •9\. Documented in\-utero teratogen, substance, and/or alcohol exposure, which in the opinion of the Investigator may increase the participant’s risk of developmental delays, congenital anomalies, and/or significant medical complications
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Open-label, Dose Escalation Study of GB1275 Alone and in Combination with Anti-PD 1 Antibody in Patients with Advanced Solid Tumors or in Combination with Standard of Care with Patients with Metastatic Pancreatic Adenocarcinoma, Followed by a Dose Expansion of GB1275 with Standard of Care or in Combination with an Anti-PD-1 Antibody in Patients with Metastatic Solid TumorsPhase 1: Advanced solid tumors, metastatic pancreatic adenocarcinomaPhase 2: Specified metastatic solid tumorsTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2019-001879-37-GBGB006, Inc., a wholly-owned subsidiary of Gossamer Bio, Inc.242
Active, not recruiting
Phase 1
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid TumoursMelanoma, Head and Neck Squamous Cell Carcinoma, Solid tumors, Pancreatic Ductal Adenocarcinoma, Colorectal CancerMedDRA version: 21.1Level: LLTClassification code: 10051971Term: Pancreatic adenocarcinoma Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10053571Term: Melanoma Class: 10029104MedDRA version: 21.0Level: PTClassification code: 10061451Term: Colorectal cancer Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104MedDRA version: 21.1Level: PTClassification code: 10067821Term: Head and neck cancer Class: 100000004864Therapeutic area: Diseases [C] - Neoplasms [C04]CTIS2023-506228-10-00Ipsen Pharma60
Active, not recruiting
Phase 1
A Dose Escalation Study of Talquetamab in Participants with Relapsed or Refractory Multiple MyelomaEUCTR2017-002400-26-FRJanssen-Cilag International NV403
Active, not recruiting
Phase 1
A dose-finding study to evaluate mRNA-3210 in participants with phenylketonuriaCTIS2023-506963-32-00Moderna Therapeutics Inc.54
Recruiting
Phase 2
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple MyelomaMultiple Myeloma10018865NL-OMON54560Janssen-Cilag24